Skip to main content

FDA Approvals

FDA Approvals, Lung Cancer, Oncology

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

FDA Approvals, Lung Cancer, Oncology

Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC

Tabrecta First FDA-Approved Targeted Therapy for Metastatic NSCLC and MET Exon 14 Skipping

Retevmo First Therapy Approved for 3 Types of Cancers with RET Mutations

FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications

Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer

FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma

FDA Approvals, Urothelial Cancer, Oncology

Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer

Sarclisa Newest Treatment Approved by the FDA for Patients with Multiple Myeloma

Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome

Wayne Kuznar

Page 17 of 53
Results 161 - 170 of 522